

- [CTVD Membership Update](#)
- [Annual CTVD Meeting](#)
- [CTVD Portal](#)
- [Research Community Update](#)
- [Recent BMGF News](#)
- [5th Global Forum on TB Vaccines Recap](#)
- [H4:IC31 Vaccine/BCG Revaccination Clinical Trial Results](#)
- [TB R&D Funding Targets Announced in Moscow](#)
- [Upcoming Virtual Forums](#)
- [Early Career Scientist Award](#)
- [Visiting Scientist Program](#)
- [CTVD Advisory Council](#)
- [GH-VAP](#)
- [Publications of Interest](#)
- [Feedback](#)

CTVD Membership Update

We currently have 55 member institutions, with over 250 individual members, and are still growing.

Annual CTVD Meeting

4th Annual CTVD Meeting
June 20 - 22, 2018
Seattle, Washington



The 4th CTVD Annual Meeting will be held at the Gates Foundation in Seattle, WA June 20-22, 2018! Research Community members only will meet on June 20 and the general meeting will convene June 21-22. We look forward to this opportunity to discuss recent advances in the field of TB Vaccine discovery and consider strategies for moving the field forward. This meeting is by invitation only, with a junior investigator application process. For more information, please contact Ksenia Koon at kkoon@ctvd.co.

- To view a draft agenda of the 2018 program, please click [Agenda](#).
- To view presentations from the 2017 annual meeting, please visit [CTVD Meetings](#)

CTVD Portal

Have you missed previously recorded CTVD Virtual Forums or Meetings? Want to view documents from your Research Community (RC) or take part in your RC discussions through the discussions boards? Access to the secure portal is available to CTVD members whose institution has signed the DMSA (data and materials sharing agreement). There is an expectation that data arising from CTVD services and GH-VAP services be shared in a manner consistent with the Data Sharing Principles. Visit the CTVD Portal, located in the upper right-hand corner of the CTVD home page, <https://www.ctvd.co>, to access all this information and more. Forgot your logon? Contact Ksenia Koon (kkoon@ctvd.co), CTVD Manager, for help.

Research Community Update

CTVD has traditionally had six research communities (RC), however we have just launched our seventh RC, the innate immunity RC. These research communities are involved in identifying and mapping critical research priorities for TB vaccine discovery and development. Each community is mandated with discussing the issues at hand and devising priority areas to address. We, at the Gates Foundation, champion these research communities and investigate avenues to fund these priorities. The co-chairs of the new innate immunity RC are Mihai Netea and Shabaana Khader. If you have questions about any of the research communities, please ask one of the co-chairs.

Aerosol and Mucosal Vaccination: Aurelio Bonavia | Steffen Stenger

B-cells and Antibodies: Bryan Charleston | Steve Porcelli

Conventional T cells: Helen Fletcher | Kevin Urdahl

Donor-Unrestricted T Cells: Dave Lewinsohn | Branch Moody

Innate Immunity: Mihai Netea | Shabaana Khader

Non-Human Primates: Trisha Darrah | Dominick Laddy
Whole Cell TB Vaccines: Olivier Neyrolles | Roland Brosch

Recent BMGF News

As many of you are already aware, we have some upcoming changes to our TB program at the Gates Foundation. Gilla Kaplan retired and on April 2, 2018, Emilio Emini stepped in as Director of the TB Program in addition to his current responsibilities as Director of the HIV Program. Emilio's decades of expertise in infectious diseases and in product development make him an excellent choice to lead our TB team to effectively deliver existing tools and successfully move promising new candidates through the development cycle to reach patients.

5th Global Forum on TB Vaccines Recap

The [5th Global Forum on TB Vaccines](#) took place in New Delhi, India from 20 – 23 February 2018, bringing together nearly 350 researchers, product developers, policy makers, advocates, and other stakeholders from 31 countries to discuss the latest research and findings in the field, to discuss the path forward for this critical research, and to foster new partnerships and collaborations. There was a sense of optimism among the participants as new data was announced and new research and approaches were shared.

Presentations from the 5th Global Forum on TB Vaccines are now available [online](#).

H4:IC31 Vaccination/BCG Revaccination Clinical Trial Results

During the February 2018 5th Global Forum on TB Vaccines in New Delhi, Aeras held a panel discussion on the H4:IC31 Vaccination/BCG Revaccination Clinical Trial Results. The following panelists presented:

- Mark Hatherill, Director, South African Tuberculosis Vaccine Initiative (SATVI)
- Sanjay Gurunathan, Associate Vice President, Global Clinical Development, Sanofi Pasteur
- Ann Ginsberg, Chief Medical Officer, Aeras
- Carl Dieffenbach, Director of the Division of AIDS, NIAID
- Gavin Churchyard, Founder and CEO, The Aurum Institute

To view the full video, as well as panelists' closing comments, please visit <https://www.youtube.com/watch?v=j4Iqvau5cpQ>

To view a 3 minute clip of just the panelists' closing comments, please visit <https://youtu.be/k35N6Xgg4nU>

TB R&D Funding Targets Announced in Moscow

Ahead of the first WHO Global Ministerial Conference, [Ending tuberculosis in the SDG era: a multisectoral response](#), in Moscow, Russian Federation, on 16–17 November 2017, Treatment Action Group (TAG) released their 2016 TB research funding trends [report](#), which highlighted major gaps that must be filled in order to meet [Global Plan to End TB](#) targets. In 2016, diagnostics R&D received just \$79.8 million of the substantial \$3.4 billion that is needed by 2020. Major funding shortfalls were also evident in treatment and vaccine R&D.

At this conference, 120 national delegations, including Ministers of Health, joined leaders of UN organizations, development agencies, regional bodies and NGOs, to discuss how to accelerate implementation of the [WHO End TB Strategy](#).

R&D panel discussion, including a talk from Tony Fauci NIAID, can be accessed at <https://www.youtube.com/watch?v=hrA9CmIQ4iw> and other talks from the meeting <http://endtbrussia.org/>

Upcoming Virtual Forums

The CTVD holds monthly virtual forums aimed at keeping our members informed of exciting advances in the field. If you have ideas for topics/speakers for upcoming virtual forums, please send them our way!

Note the upcoming virtual forum presenter and date. All forums are held at 8am pacific time. Login details will be sent to CTVD members prior to each forum.

May 24, 2018—Sebastien Gagneaux, "Population genomics of Mtb and the implications of host adaptation for the development of effective TB vaccines"

To view the most recent webinar, visit CTVD portal, located in the upper right-hand corner of the CTVD home page, at <https://www.ctvd.co>.

Early Career Scientist Award

Today's early career scientists are essential to ensure that the field remains innovative, scientifically robust, and to infuse new ways of approaches to tackle the scientific challenges in order to develop a TB vaccine. The CTVD has implemented a process, the CTVD Early Career Scientist Award, to recognize the efforts of early career scientists who have made significant contributions to research in TB host-pathogen biology, immunology, and vaccinology. The Early Career Scientist award carries with it a travel grant to attend a TB-related conference. This award will cover expenses related to registration and travel (air flight, lodging, and

meals).

All nominations must be submitted electronically via the link below. Nominations will not be accepted by email or by post. Please submit your nominations today!

<https://www.ctvd.co/Pages/EarlyCareerScientistAward.aspx>

Visiting Scientist Program

The Visiting Scientist Program (VSP) enables scientists from different CTVD member institutions to embrace new scientific concepts and gain experience in novel technologies with an overarching goal of promoting the exchange of ideas, expertise, and experiences. Through the VSP, scientists from CTVD member institutions from around the world are invited, as visiting scientists, to spend from 1 week to a maximum of 3 weeks and participate in established research studies in a laboratory of a CTVD member institution of their choice. Visiting scientists and the host scientists will jointly develop a coordinated agenda and training schedule, which is tailored to address their area of expertise and/or the specific techniques, instruments or innovations they want to learn.

Please visit <https://www.ctvd.co/Pages/VisitingScientistProgram.aspx> for more information and to apply!

CTVD Advisory Council

The CTVD Advisory Council is comprised of the co-chairs from each of the seven research communities, plus a representative from TBVI. The Advisory Council meets semi-annually and guides the direction of CTVD.

GH-VAP

The Global Health Vaccine Accelerator Platform (GH-VAP) program provides investigators with access to several specialized research platforms to accelerate vaccine discovery and translation across infectious disease areas. To learn more, visit GH-VAP at <https://www.ghvap.org>

Publications of Interest

Do you have an article that you think the CTVD community would enjoy reading? If so, please let us know. We welcome your contributions of publications of interest for upcoming newsletters and our website.

Feedback

If you have questions or comments, please contact the CTVD program manager at kkoon@ctvd.co

[CTVD.co](http://ctvd.co) | [CTVD Portal](#) | [Support](#)

© 2018 - Collaboration for TB Vaccine Discovery

content and editing by K. Koon

layout and design by B. Sanders

Unsubscribe to CTVD announcements, [click here](#)